Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

10.39
+0.48004.84%
Volume:4.29M
Turnover:44.56M
Market Cap:604.06M
PE:-4.21
High:11.00
Open:10.77
Low:10.07
Close:9.91
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:0.53
T/O Rate:9.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.45
PE(LYR):-4.60

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Capricor Therapeutics (CAPR), Enovis (ENOV) and Progyny (PGNY)

TIPRANKS
·
May 09

Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy

Benzinga
·
May 08

H.C. Wainwright Sticks to Its Buy Rating for Capricor Therapeutics (CAPR)

TIPRANKS
·
May 08

Capricor sues Nippon Shinyaku over US distribution rights for CAP-1002

Reuters
·
May 08

Capricor Therapeutics Inc - Alleges Ns Pharma Failed to Prepare for Deramiocel Launch and Breached Agreement - SEC Filing

THOMSON REUTERS
·
May 08

Capricor Therapeutics Inc - Files Lawsuit and Seeks Preliminary Injunction in New Jersey Court on May 7, 2026 - SEC Filing

THOMSON REUTERS
·
May 08

Earning Preview: Capricor Therapeutics this quarter’s revenue is expected to decrease by 100%, and institutional views are bullish

Earnings Agent
·
May 06

Capricor CFO Anthony Bergmann disposes of 25,000 shares worth $792,540

Reuters
·
May 05

Capricor EVP, General Counsel Karen Krasney disposes 25,000 shares for $792,548‬

Reuters
·
May 05

Capricor Therapeutics schedules first-quarter 2026 financial results conference call and webcast

Reuters
·
May 05

Press Release: Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

Dow Jones
·
May 05

Capricor Therapeutics (CAPR) Is Down 12.4% After New HOPE-3 Deramiocel Phase 3 Data Release - What's Changed

Simply Wall St.
·
May 03

Capricor reports Phase 3 HOPE-3 trial results for Deramiocel in Duchenne muscular dystrophy

Reuters
·
Apr 22

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

GlobeNewswire
·
Apr 22

Capricor Therapeutics (CAPR) Gets a Buy from Roth MKM

TIPRANKS
·
Apr 15

Capricor director Karimah Es Sabar disposes of $0.2 million common shares

Reuters
·
Apr 04

Capricor director Karimah Es Sabar disposes of common shares worth $3.5 million

Reuters
·
Apr 02

Capricor EVP, General Counsel Karen Krasney disposes of CAPR shares worth $0.8 million

Reuters
·
Apr 02

Capricor CFO Anthony Bergmann disposes of $0.8 million in common shares

Reuters
·
Apr 02

Capricor Therapeutics announces annual shareholder meeting, issues proxy statement

Reuters
·
Apr 01